 Armata Pharmaceuticals, Inc. NYSE American: ARMP Armata or the Company, a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received a 15 million award for a three year program from the U.S. DoD through the Medical Technology Enterprise Consortium MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. Armata will use the award to partially fund a Phase 1b2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armatas therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections. 